The advantage of antibody cocktails for targeted alpha therapy depends on specific activity

Journal of Nuclear Medicine

Volumn 55, Issue 12, 2014, Pages 2012-2019

  Pasternack, Jordan B ^a   Domogauer, Jason D ^a   Khullar, Alisha ^a   Akudugu, John M ^b   Howell, Roger W ^a  

^a New Jersey Medical School University Hospital Cancer Center   (United States)

^b STELLENBOSCH UNIVERSITY   (South Africa)

Author keywords

Alpha particle; Antibody cocktails; Disseminated tumor cells; Flow cytometry; Isolated tumor cells; Monte Carlo; Radioimmunotherapy; Radionuclide; Specific activity; Targeted alpha therapy

Indexed keywords

FLUOROCHROME; MONOCLONAL ANTIBODY; ACTINIUM; ANTIBODY; ASTATINE; BISMUTH; DRUG COMBINATION; RADIOISOTOPE; RADIOPHARMACEUTICAL AGENT;

ALPHA RADIATION; ARTICLE; BREAST CANCER; CANCER CELL; CANCER THERAPY; CELL KILLING; CELL SURVIVAL; CONTROLLED STUDY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; ISOTOPE LABELING; METHODOLOGY; MONTE CARLO METHOD; RADIATION DOSE DISTRIBUTION; RADIOIMMUNOTHERAPY; ALGORITHM; BREAST NEOPLASMS; DRUG COMBINATION; DRUG EFFECTS; FEMALE; METABOLISM; PROCEDURES; RADIATION RESPONSE; THERAPEUTIC USE; TUMOR CELL LINE;

ACTINIUM; ALGORITHMS; ALPHA PARTICLES; ANTIBODIES; ASTATINE; BISMUTH; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL SURVIVAL; DRUG COMBINATIONS; FEMALE; HUMANS; RADIOIMMUNOTHERAPY; RADIOISOTOPES; RADIOPHARMACEUTICALS;

EID: 84915745342     PISSN: 01615505     EISSN: 2159662X     Source Type: Journal    
DOI: 10.2967/jnumed.114.141580     Document Type: Article

References (34)

1. Sharkey RM, Goldenberg DM. Cancer radioimmunotherapy. Immunotherapy. 2011;3:349-370.
2. Kvinnsland Y, Stokke T, Aurlien E. Radioimmunotherapy with alpha-particle emitters: microdosimetry of cells with a heterogeneous antigen expression and with various diameters of cells and nuclei. Radiat Res. 2001;155:288-296.
3. Neti PV, Howell RW. Log normal distribution of cellular uptake of radioactivity: implications for biologic responses to radiopharmaceuticals. J Nucl Med. 2006;47:1049-1058.
4. 211At-labeled trastuzumab in human breast cancer cell lines: effect of specific activity and HER2 receptor heterogeneity on survival fraction. Nucl Med Biol. 2006;33:333-347.
5. Sgouros G, Scheinberg DA. Treatment of leukemia with radiolabeled monoclonal antibodies. Cancer Treat Res. 1993;68:23-64.
6. Akudugu JM, Howell RW. Flow cytometry-assisted Monte Carlo simulation predicts clonogenic survival of cell populations with lognormal distributions of radiopharmaceuticals and anticancer drugs. Int J Radiat Biol. 2012;88:286-293.
7. Wan L, Pantel K, Kang Y. Tumor metastasis: moving new biological insights into the clinic. Nat Med. 2013;19:1450-1464.
8. Hayashi N, Yamauchi H. Role of circulating tumor cells and disseminated tumor cells in primary breast cancer. Breast Cancer. 2012;19:110-117.
9. Singletary SE, Connolly JL. Breast cancer staging: working with the sixth ed. of the AJCC Cancer Staging Manual. CA Cancer J Clin. 2006;56:37-47; quiz 50-31.
10. Blumenthal RD, Kashi R, Stephens R, Sharkey RM, Goldenberg DM. Improved radioimmunotherapy of colorectal cancer xenografts using antibody mixtures against carcinoembryonic antigen and colon-specific antigen-p. Cancer Immunol Immunother. 1991;32:303-310.
11. 131I-labeled monoclonal antibody therapy with interferon in patients with metastatic colorectal cancer. Clin Cancer Res. 1996;2:1811-1818.
12. 90Y-labeled HLA-DR antibodies. Clin Cancer Res. 2005;11:7075s-7079s.
13. Milenic DE, Brady ED, Garmestani K, Albert PS, Abdulla A, Brechbiel MW. Improved efficacy of alpha-particle-targeted radiation therapy: dual targeting of human epidermal growth factor receptor-2 and tumor-associated glycoprotein 72. Cancer. 2010;116:1059-1066.
14. Pagel JM, Pantelias A, Hedin N, et al. Evaluation of CD20, CD22, and HLA-DR targeting for radioimmunotherapy of B-cell lymphomas. Cancer Res. 2007;67:5921-5928.
15. 210Po. Nucl Med Biol. 2012;39:954-961.
16. Akudugu JM, Neti PVSV, Howell RW. Changes in lognormal shape parameter guide design of patient-specific radiochemotherapy cocktails. J Nucl Med. 2011;52:642-649.
17. Powell AA, Talasaz AH, Zhang H, et al. Single cell profiling of circulating tumor cells: transcriptional heterogeneity and diversity from breast cancer cell lines. PLoS ONE. 2012;7:e33788.
18. Grover-McKay M, Walsh SA, Seftor EA, Thomas PA, Hendrix MJ. Role for glucose transporter 1 protein in human breast cancer. Pathol Oncol Res. 1998;4:115-120.
19. Osta WA, Chen Y, Mikhitarian K, et al. EpCAM is overexpressed in breast cancer and is a potential target for breast cancer gene therapy. Cancer Res. 2004;64:5818-5824.
20. Vaziri B, Wu H, Dhawan AP, Du P, Howell RW. MIRD pamphlet no. 25: MIRDcell V2.0 software tool for dosimetric analysis of biologic response of multicellular populations. J Nucl Med. 2014;55:1557-1564.
21. 213Bi-labeled antibody constructs for clinical use. J Nucl Med. 1999;40:1722-1727.
22. 225Ac radioimmunopharmaceuticals. Appl Radiat Isot. 2002;57:841-847.
23. Koefoed K, Steinaa L, Soderberg JN, et al. Rational identification of an optimal antibody mixture for targeting the epidermal growth factor receptor. MAbs. 2011;3:584-595.
24. Murray NP, Reyes E, Tapia P, et al. Redefining micrometastasis in prostate cancer: a comparison of circulating prostate cells, bone marrow disseminated tumor cells and micrometastasis - implications in determining local or systemic treatment for biochemical failure after radical prostatectomy. Int J Mol Med. 2012;30:896-904.
25. Mathiesen RR, Borgen E, Renolen A, et al. Persistence of disseminated tumor cells after neoadjuvant treatment for locally advanced breast cancer predicts poor survival. Breast Cancer Res. 2012;14:R117.
26. Lee JL, Wang MJ, Chen JY. Acetylation and activation of STAT3 mediated by nuclear translocation of CD44. J Cell Biol. 2009;185:949-957.
27. Wang Q, Villeneuve G, Wang Z. Control of epidermal growth factor receptor endocytosis by receptor dimerization, rather than receptor kinase activation. EMBO Rep. 2005;6:942-948.
28. Stagg J, Divisekera U, McLaughlin N, et al. Anti-CD73 antibody therapy inhibits breast tumor growth and metastasis. Proc Natl Acad Sci USA. 2010;107:1547-1552.
29. Terp MG, Olesen KA, Arnspang EC, et al. Anti-human CD73 monoclonal antibody inhibits metastasis formation in human breast cancer by inducing clustering and internalization of CD73 expressed on the surface of cancer cells. J Immunol. 2013;191:4165-4173.
30. Goddu SM, Howell RW, Rao DV. Cellular dosimetry: absorbed fractions for monoenergetic electron and alpha particle sources and S-values for radionuclides uniformly distributed in different cell compartments. J Nucl Med. 1994;35:303-316.
31. 210Po in multicellular clusters. Radiat Res. 2007;168:332-340.
32. 213Bi)-labeled anti-prostate-specific membrane antigen antibody (J591). Cancer Res. 2001;61:2008-2014.
33. Wessels BW, Rogus RD. Radionuclide selection and model absorbed dose calculations for radiolabeled tumor associated antibodies. Med Phys. 1984;11:638-645.
34. 211At-labeled antibodies with an epsilon-lysyl-3-(trimethylstannyl) benzamide immunoconjugate. J Nucl Med. 2008;49:1537-1545.